Table 4.
Efficacy results in the dose-escalation and dose-expansion cohorts receiving the same dose combined.
| Mogamulizumab 1 mg/kg + durvalumab 10 mg/kg (n = 19) |
Mogamulizumab 1 mg/kg + tremelimumab 10 mg/kg (n = 19) |
|
|---|---|---|
| ORR, n (%) [95% CI] | 1 (5.3) [0.1, 26.0] | 1 (5.3) [0.1, 26.0] |
| CR, n (%) | 0 | 0 |
| PR, n (%) | 1a (5.3) | 1b (5.3) |
| SD, n (%) | 5 (26.3) | 7 (36.8) |
| PD, n (%) | 12 (63.2) | 9 (47.4) |
| NE, n (%) | 1 (5.3) | 2 (10.5) |
| Median OS, months (95% CI) | 8.9 (4.3, 18.4) | 4.4 (2.5, 13.4) |
| Median PFS, months (95% CI) | 1.9 (1.7, 4.4) | 1.9 (1.4, 3.7) |
a
Duration of response was 10.6 months and time to response was 3.68 months in a patient with alveolar soft part sarcoma.
b
Duration of response was 3.7 months and time to response was 1.84 months in a patient with prostate cancer.
CI, confidence interval; CR, complete response; NE, not evaluable; PD, progressive disease; PFS, progression-free survival; PR, partial response; OS, overall survival; SD, stable disease.